Next Gen RNA
Vaccines and Therapeutics

Tiba Biotech is advancing the RNA medicine field with an improved approach to nucleic acid delivery.
Fully biodegradable nanoparticle delivery platform for safer vaccines and therapeutics
Computational RNA design for more potent gene expression
Better patient outcomes through rational design, from gene to delivery method
bt_bb_section_bottom_section_coverage_image
Novel delivery platform

Novel delivery platform

5+ years government sponsored research
Vaccines and therapeutics

Vaccines and therapeutics

Broad range of applications
Advanced RNA Design

Advanced RNA Design

State-of-the-art engineering

CORE INNOVATIONIntegrated nanoparticle delivery and nucleic acid design

Enabling life-saving vaccines and new areas of therapeutic impact

Tiba Biotech is developing a range of novel vaccines, with initial focus on the COVID-19 pandemic, the persistent challenge of seasonal influenza, and emerging zoonotic threats. Our collaborators and strategic partners include:

  • United States National Institute of Health  (NIH)
  • Collaborative Influenza Vaccine Innovation Centers (CIVICs)
  • United States Army Medical Research Institute of Infectious Diseases (USAMRIID)
  • The Bill and Melinda Gates Foundation (BMGF)
  • Canada’s International Development Research Centre (IDRC)
https://i0.wp.com/tiba.bio/wp-content/uploads/2020/06/large_blue_triangle_04.png?fit=484%2C481&ssl=1
bt_bb_section_bottom_section_coverage_image

BEYOND VACCINESLeveraging High-efficiency Next Generation RNA Delivery for Therapeutic Applications

Engaged in early discovery of immuno-oncology and gene delivery
bt_bb_section_top_section_coverage_image